336 related articles for article (PubMed ID: 31786833)
21. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
de Mello RA; Marques AM; Araújo A
World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
[TBL] [Abstract][Full Text] [Related]
22. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.
Ragusa M; Majorana A; Statello L; Maugeri M; Salito L; Barbagallo D; Guglielmino MR; Duro LR; Angelica R; Caltabiano R; Biondi A; Di Vita M; Privitera G; Scalia M; Cappellani A; Vasquez E; Lanzafame S; Basile F; Di Pietro C; Purrello M
Mol Cancer Ther; 2010 Dec; 9(12):3396-409. PubMed ID: 20881268
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
25. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Weinberg BA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
[No Abstract] [Full Text] [Related]
26. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
27. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
28. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
29. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
30. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of panitumumab in refractory metastatic colorectal cancer: A meta-analysis.
Duan KF; Wang H
J BUON; 2019; 24(4):1457-1463. PubMed ID: 31646791
[TBL] [Abstract][Full Text] [Related]
32. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
33. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Köstek O; Demircan NC; Gökyer A; Küçükarda A; Sunal BS; Hacıoğlu MB; Eslame H; Solak S; Yılmaz E; Uzunoğlu S; Tunçbilek N; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1510-1517. PubMed ID: 30924091
[TBL] [Abstract][Full Text] [Related]
34. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
36. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
37. The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'.
Basso M; Dadduzio V; Rossi S; D'Argento E; Strippoli A; Di Salvatore M; Orlandi A; Zurlo V; Di Noia V; Barone C
Per Med; 2018 Jul; 15(4):319-327. PubMed ID: 29927360
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
[No Abstract] [Full Text] [Related]
39. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
[TBL] [Abstract][Full Text] [Related]
40. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
Tímár J; Láng I
Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
